An affordable hepatitis C combination treatment including the new drug candidate ravidasvir has been shown to be safe and effective, with extremely high cure rates for patients, including hard - to - treat cases, according to interim results from the Phase II / III STORM - C - 1 trial presented by the non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) at the International Liver Conference in Paris. (sciencedaily.com)
«We are achieving the same or higher cure rates in many patients with sofosbuvir, compared to interferon, and we are doing it in half the time with a drug that has a remarkable safety profile.» (sciencedaily.com)
Cumulative burden should help researchers refine health screening guidelines for survivors and design clinical trials aimed at maintaining high cure rates while reducing the late effects of treatment. (sciencedaily.com)